Esperion to Report Third Quarter 2024 Financial Results on November 7
Esperion (NASDAQ: ESPR) has announced it will report its third quarter 2024 financial results on Thursday, November 7, 2024, before market opens. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates. A live audio webcast will be accessible through Esperion's website, with the replay available for approximately 90 days after the call. The company focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol treatment.
Esperion (NASDAQ: ESPR) ha annunciato che riporterà i propri risultati finanziari del terzo trimestre 2024 giovedì 7 novembre 2024, prima dell'apertura del mercato. L'azienda ospiterà un webcast alle 8:00 a.m. ET per discutere i risultati e fornire aggiornamenti sulle attività. Un webcast audio in diretta sarà accessibile tramite il sito web di Esperion, con la registrazione disponibile per circa 90 giorni dopo la chiamata. L'azienda si concentra sullo sviluppo di medicine innovative per le malattie cardiovascolari e cardiometaboliche, con particolare attenzione al trattamento dell'ipercolesterolemia.
Esperion (NASDAQ: ESPR) ha anunciado que informará sobre sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024, antes de la apertura del mercado. La compañía realizará un webcast a las 8:00 a.m. ET para discutir los resultados y proporcionar actualizaciones comerciales. Un webcast de audio en vivo estará disponible a través del sitio web de Esperion, con la repetición accesible durante aproximadamente 90 días después de la llamada. La empresa se centra en desarrollar medicamentos innovadores para enfermedades cardiovasculares y cardiometabólicas, dirigiéndose específicamente al tratamiento del colesterol alto.
Esperion (NASDAQ: ESPR)는 2024년 11월 7일 목요일, 시장 개장 전에 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 이 회사는 오전 8시(ET)에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 웹캐스트를 주최할 것입니다. 라이브 오디오 웹캐스트는 Esperion의 웹사이트를 통해 접근할 수 있으며, 통화 후 약 90일 동안 다시 듣기가 가능합니다. 이 회사는 심혈관 및 심혈관 대사 질환을 위한 혁신적인 의약품 개발에 집중하고 있으며, 특히 고콜레스테롤 치료를 목표로 하고 있습니다.
Esperion (NASDAQ: ESPR) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le jeudi 7 novembre 2024, avant l'ouverture du marché. L'entreprise organisera un webcast à 8h00 ET pour discuter des résultats et fournir des mises à jour commerciales. Un webcast audio en direct sera accessible via le site web d'Esperion, avec une rediffusion disponible pendant environ 90 jours après l'appel. L'entreprise se concentre sur le développement de médicaments innovants pour les maladies cardiovasculaires et cardiométaboliques, visant particulièrement le traitement de l'hypercholestérolémie.
Esperion (NASDAQ: ESPR) hat angekündigt, dass die finanziellen Ergebnisse für das dritte Quartal 2024 am Donnerstag, den 7. November 2024, vor Markteröffnung veröffentlicht werden. Das Unternehmen wird um 8:00 Uhr ET ein Webcast veranstalten, um die Ergebnisse zu besprechen und Unternehmensupdates bereitzustellen. Ein Live-Audio-Webcast wird über die Website von Esperion zugänglich sein, und die Aufzeichnung wird ungefähr 90 Tage nach dem Anruf verfügbar sein. Das Unternehmen konzentriert sich auf die Entwicklung innovativer Medikamente für Herz-Kreislauf- und kardiometabolische Krankheiten, insbesondere zur Behandlung von hohem Cholesterin.
- None.
- None.
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
This press release was published by a CLEAR® Verified individual.
FAQ
When will Esperion (ESPR) report Q3 2024 earnings?
What time is Esperion's (ESPR) Q3 2024 earnings call?
How long will Esperion's (ESPR) Q3 2024 earnings webcast replay be available?
